ReviewPathogens (Basel, Switzerland)2023
From Innovation to Implementation: The Evolution of HIV Pre-Exposure Prophylaxis and Future Implications.
Review in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Retrospective analysis of HIV pre-exposure prophylaxis (PrEP) awards under Executive Order 14168 on gender ideology in the U.S. 2012-2025.Public health in practice (Oxford, England) · 2026Article
- Article
- Review
- Co-creating the clinical pathway for Test it, a web-accessed sexually transmitted infections testing service.NPJ digital medicine · 2026Article
- How PrEPared is our campus? Insights from a cross-sectional study on awareness and attitudes towards HIV pre-exposure prophylaxis (PrEP) amongst University of Saskatchewan (Canada) students.BMC infectious diseases · 2026Article
- Call to action: A roadmap for HIV prevention and PrEP adoption in the Gulf region.International journal of STD & AIDS · 2026Review
- Barriers to PrEP use and adherence among adolescent girls and young women in Eastern, Southern, and Western Africa: a scoping review.BMC women's health · 2024Article
- Evaluating Equity-Centered Capacity-Building Programs to Strengthen Implementation Leadership in Southern U.S. HIV Service Organizations.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-exposure prophylaxis (PrEP) is a highly effective HIV-prevention strategy that involves the continuous administration of antiretroviral drugs to HIV-negative individuals with a substantial risk of contracting an HIV infection. The use of PrEP has shown a reduction in the risk of HIV acquisition through sexual intercourse by up to 99%. Despite its effectiveness, PrEP uptake remains low among populations at high risk of HIV infection. This highlights the need for further research in strategies to enhance awareness and uptake of PrEP amongst these specific populations. This article presents a comprehensive overview of the existing literature on the effectiveness of PrEP in reducing HIV transmission rates. Additionally, we examine the obstacles related to PrEP implementation and uptake and put forward potential strategies to raise awareness and improve its use among populations at an increased risk of contracting HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.